National Cancer Institute

Cancer Control and Population Sciences - NCI's bridge to public health research, practice and policy

Cancer Control and Population Sciences Home

Funding Opportunities

Need Help? Contact us by phone (1-800-422-6237), Web, or e-mail

Frequently Asked Questions:
NOT-CA-08-011 (Administrative Supplements for Gene Identification Efforts: Replication and Fine-Mapping Studies for The Genes, Environment, and Health Initiative (GEI))





Should genotyping costs be included in the budget?
The National Institutes of Health (NIH) intends to commit approximately $400,000 in total costs per project, including genotyping costs. If applicants expect to have their genotyping done at a center funded by The Genes, Environment, and Health Initiative (GEI), then genotyping costs need not be included in the application budget; however genotyping costs should be reflected in the research plan.

Assuming my genotyping will be done at a GEI-funded genotyping center, what pricing information should I use to estimate genotyping costs?
For project planning purposes, refer to the following pricing guidelines:

For further information, contact Daniel Mirel (dbmirel@broad.mit.edu) or Stacey Gabriel (stacey@broad.mit.edu) at the Broad Institute, and Alan F. Scott (afscott@jhmi.edu) at CIDR.

If my grant ends prior to September 1, 2009 (the estimated end date for 12 month supplemental awards) am I still eligible to apply for an administrative supplement?
As noted in the original announcement, the "parent" award must remain active during the entire funding period of this supplement. Investigators may apply for a 1-year no cost extension of the "parent" award or, if feasible, propose a funding period of less than 12 months which would coincide with the remaining funding period for the "parent grant."

What if my genome-wide association study’s (GWAS) results are not available prior to the application due date of May 1, 2008?
If applicants anticipate that their GWAS results will be available prior to the expected award date for the supplement (September 1, 2008), applicants may apply for replication and fine mapping support, provided they (1) submit clearly identified criteria (including quality control) for the selection of the loci to be replicated; (2) genotyping will be completed at a GEI-funded genotyping center; and (3) applicants address the issue of the power needed in the replication sample to detect an appropriate range of genetic effects.


Last Updated: April 9, 2008

 

Search | Help | Contact Us | Accessibility | Privacy Policy

DCCPSNational Cancer Institute Department of Health and Human Services National Institutes of Health USA.gov

 
DCCPS Home